Recent clinical trials have demonstrated efficacy and safety of etrasimod, a new sphingosine-1-phosphate receptor modulator, in the treatment of patients with moderately-to-severely active ulcerative colitis. Etrasimod is a promising new oral treatment option for ulcerative colitis, although long-term efficacy and safety data should be accumulated.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
03 July 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41575-023-00817-9
References
Kirchgesner, J. et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment. Pharmacol. Ther. 45, 37–49 (2017).
Kobayashi, T. et al. Ulcerative colitis. Nat. Rev. Dis. Primers 6, 74 (2020).
Grossberg, L. B., Papamichael, K. & Cheifetz, A. S. Review article: emerging drug therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. https://doi.org/10.1111/apt.16785 (2022).
Sandborn, W. J. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754–1762 (2016).
Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet https://doi.org/10.1016/s0140-6736(23)00061-2 (2023).
Lasa, J. S., Olivera, P. A., Danese, S. & Peyrin-Biroulet, L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7, 161–170 (2022).
Buisson, A. et al. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izac119 (2023).
Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
Matsuoka, K. et al. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. J. Gastroenterol. Hepatol. https://doi.org/10.1111/jgh.15923 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.H. has received lecture fees from AbbVie, EA Pharma, Janssen, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz, Takeda Pharmaceutical and Zeria, advisory/consultancy fees from AbbVie, Celltrion Healthcare, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi Tanabe Pharma, Nichi-Iko, Nippon Kayaku, Takeda Pharmaceutical and Zeria, and research grants from AbbVie, Activaid, Alfresa Pharma, Bristol-Myers Squibb, Ferring Pharmaceuticals, Eli Lilly, Gilead Sciences, JIMRO, JMDC Inc., Janssen, Kyorin Pharmaceutical, Miyarisan, Mochida Pharmaceutical, Nippon Kayaku and Pfizer. K.M. received research grants from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Kissei Pharmaceutical, JIMRO and Nippon Kayaku, and payment or honoraria for lectures from AbbVie, EA Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Kissei Pharmaceutical, Janssen, JIMRO, Gilead Sciences, Pfizer, Takeda Pharmaceutical, Zeria, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly and Mitsubishi Tanabe Pharma.
Rights and permissions
About this article
Cite this article
Matsuoka, K., Hibi, T. Etrasimod for ulcerative colitis: evaluating phase III results. Nat Rev Gastroenterol Hepatol 20, 762–763 (2023). https://doi.org/10.1038/s41575-023-00793-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00793-0